Alzheimer's clinical trials are pivotal in advancing our understanding and treatment of Alzheimer's disease and dementia. These trials rigorously test new therapies, diagnostic tools, and interventions aimed at slowing disease progression or improving symptoms. They often involve diverse participants, ranging from those with early-stage symptoms to individuals at higher risk due to genetic factors or age.
Key objectives include evaluating safety, efficacy, and potential side effects of experimental treatments. Participants receive closely monitored care and contribute crucial data that informs future research and clinical practice. Despite challenges like patient recruitment and long trial durations, these studies are crucial for developing breakthroughs in Alzheimer's treatment. They offer hope for millions affected worldwide and drive the quest for effective therapies to alleviate the devastating impact of Alzheimer's disease and related dementias.
Title : Cerebral vascular calcium signaling in diabetic alzheimer's disease-related dementias
Yong Xiao Wang, Albany Medical College, United States
Title : Deep learning-based risk assessment of cognitive impairment using health examination data
Kaoru Sakatani, The University of Tokyo, Japan
Title : Evaluation of the neuroprotective potential of indicaxanthin from opuntia ficus indica fruit against dysmetabolism-related neurodegeneration both in vivo and in vitro
Mario Allegra, University of Palermo, Italy
Title : Cogs Club: Making a difference
Jacqueline Tuppen, Cogs Club, United Kingdom
Title : Development of imaging based biomarkers for neurovascular abnormalities in neurodegenerative diseases
Jun Hua, Johns Hopkins University School of Medicine, United States
Title : Psychosocial considerations in management of corticobasal degeneration
Esraa Askar, Forest Hills Hospital, United States